Medical cognition therapy

A cognitive decline, pharmacy technology, applied in the field of medical cognitive therapy, can solve the problems of complex functional ability decline, safety problems of aging population, safety problems and so on

Pending Publication Date: 2022-07-15
射线质医疗有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Regardless of pathophysiology, although age-related cognitive decline may not impair a person's ability to perform daily activities, it is indisputable that normal, age-related cognitive decline in healthy aging individuals...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical cognition therapy
  • Medical cognition therapy
  • Medical cognition therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0335] Example 1: Detection test

[0336] Administration of Xanaem compared to the placebo subject group TM group of subjects showed improved psychomotor function. This is done by administering Xanamm TM of the subject's improved performance rate, as evidenced by the log of the subject's correct response 10 The conversion reaction time was measured.

[0337] Figure 1A (1) and Figure 1A (2) Test scores for all subject detection trials are shown, Figure 1B (1) and Figure 1B (2) Test scores for all female subject testing trials are shown, Figure 1C (1) and Figure 1C (2) Test scores for all male subject testing tests are shown. The linear plot of the mean (±SD) detection test results at the visit of the treatment group is as follows Figure 1D shown.

Embodiment 2

[0338] Example 2: Identification Test

[0339] Administration of Xanaem compared to the placebo subject group TM M's group of subjects showed improved visual attention. This is done by administering Xanamm TM of the subject's improved performance rate, as evidenced by the log of the subject's correct response 10 The conversion reaction time was measured.

[0340] Figure 2A (1) and Figure 2A (2) Discrimination test scores for all subjects are shown, Figure 2B (1) and Figure 2B (2) Discrimination test scores for all female subjects are shown, Figure 2C (1) and Figure 2C (2) Discrimination test scores for all male subjects are shown. Figure 2D Linear plots of mean (±SD) discrimination test results at treatment group visits are shown.

Embodiment 3

[0341] Example 3: One Card Learning Test

[0342] Administration of Xanaem compared to the placebo subject group TM of subjects showed improved visual learning at week 8. This is done by administering Xanamm TM of subjects' improved performance accuracy at Week 8, as measured by the arcsine transform of the proportion of subjects' correct responses.

[0343] exist Figure 3A (1) and Figure 3A (2) the test scores of the one-card learning test for all subjects, Figure 3B (1) and Figure 3B (2) Test scores for all female subjects are shown, Figure 3C (1) and Figure 3C (2) Test scores for all male subjects are shown. Figure 3D Linear plots of mean (±SD) one-card learning test results at treatment group visits are shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present disclosure relates generally to methods of improving cognition and/or treating cognitive decline in a cognitive health subject comprising administering to a cognitive health subject a therapeutically effective amount of a compound of formula I, such as Xanamem (also referred to as UE2343), or a pharmaceutically acceptable salt, solvate, or prodrug thereof, as described herein.

Description

technical field [0001] The present invention generally relates to the field of drug therapy for improving cognition and / or treating cognitive decline in cognitively healthy subjects. The present invention also relates to methods of treating and / or preventing cognitive decline in cognitively healthy subjects. The present invention also relates to methods of improving cognitive performance in cognitively healthy subjects. Background technique [0002] Changes in cognitive abilities have been documented in the scientific literature as a normal aging process. Some cognitive abilities, such as vocabulary, resist brain aging and may even improve with age. Other cognitive abilities, such as conceptual reasoning, memory, and processing speed, may gradually decline with age. This age-related change in cognitive performance is often referred to as "age-related cognitive decline." [0003] Age-related cognitive decline is becoming a prevalent health and social problem as the popula...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/46A61P25/28
CPCA61K31/506A61P25/28A61K31/497A61K31/46A61K31/4439C07D451/02A61K31/439A61K31/444
Inventor 塔玛拉·黛安·米勒约翰·威廉·凯特尔贝
Owner 射线质医疗有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap